H.C. Wainwright reiterates Neutral on BioMarin stock, $50 target By Investing.com

BioMarin’s Phase 3 CANOPY-HCH-3 trial met its primary endpoint, showing placebo-adjusted annualized growth velocity of 2.33 cm/year at Week 52, with statistically significant gains in standing height, height Z-score, and arm span. H.C. Wainwright kept a Neutral rating but cut its price target to $50 from $55, while noting the result does not eliminate competitive pressure from Ascendis, BridgeBio, and TYRA. The next catalysts are full medical-meeting data, NDA acceptance/review timing, and any 2027 launch assumptions in guidance.

Analysis

BMRN’s hypochondroplasia readout is less about one more rare-disease win and more about de-risking a second growth leg for a franchise that has been viewed as mature. The market is still pricing VOXZOGO primarily as an achondroplasia asset, but this data suggests the addressable population can expand with relatively low incremental R&D spend, which should lift the terminal value if launch execution is credible. The key second-order effect is that payer and physician adoption may become easier if the therapy is framed as a broader pediatric height-velocity standard rather than a single-ultra-rare indication.

The competitive read-through is mixed for TYRA: the data validates the biological concept for CNP/FGFR3-targeting programs, but BioMarin’s first-mover advantage means competitors now have to justify not just efficacy, but superiority in durability, safety, dosing convenience, and label breadth. In this segment, being second with similar efficacy is usually a commercial disadvantage because treatment centers are concentrated and switching costs are behavioral, not just clinical. That said, if competitors can show better growth velocity in a different genotype mix or less frequent dosing, BioMarin’s advantage could compress faster than the headline suggests.

The main risk is not the scientific signal; it is launch math and review timing. If the filing is accepted but 2027 guidance omits a meaningful contribution from hypochondroplasia, the stock can rerate back to a single-product multiple despite the pipeline win. Conversely, any delay in regulatory acceptance or conservative payer messaging would likely cap near-term upside, because investors will need evidence that this is a commercial inflection, not just another incremental indication expansion.

Consensus may be underestimating how much optionality is embedded in indication expansion for a profitable rare-disease platform. The market tends to discount rare-disease “extensions” until launch visibility hardens, but once one label expansion is approved, follow-on prescriber education and reimbursement infrastructure often carry across indications with high margin. That makes the next 6-12 months more important than the trial itself: the rerating likely comes from regulatory and guidance cadence, not from another efficacy debate.

Key Decisions for Investors

• Go long BMRN on weakness over the next 1-2 weeks; favor pullbacks toward the low-$50s. Risk/reward improves if management provides 2027 launch assumptions or positive filing timing, with upside to a higher multiple on franchise extension rather than one-off trial news.
• Buy BMRN Jan-2026 / Jan-2027 call spreads to express regulatory and guidance optionality with defined downside. Structure around strikes that capture a rerating into launch expectations rather than assuming immediate commercialization.
• Initiate a pair trade: long BMRN / short TYRA for 3-6 months. The thesis is that BioMarin now owns the de-risked commercial lead, while TYRA remains more execution-dependent and valuation is more sensitive to comparative efficacy and label differentiation.
• Trim or short TYRA into strength if the market extrapolates class validation too aggressively. The risk/reward is favorable only if TYRA can show a materially better profile on dosing or durability, which is not yet in hand.
• Add a catalyst watch for FDA/NDA acceptance and 2027 guidance commentary. If either is delayed or absent, take profits on BMRN longs because the stock can revert to mature-franchise multiples quickly.